To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Inotrem expands Series B
Paris-based Inotrem S.A., which specializes in immunotherapy for acute and chronic inflammatory syndromes, has expanded its Series B funding to 58 million euros.
